Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms

Shi, 2017, Cancer nanomedicine: progress, challenges and opportunities, Nat. Rev. Cancer, 17, 20, 10.1038/nrc.2016.108

Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat. Nanotechnol., 2, 751, 10.1038/nnano.2007.387

Min, 2015, Clinical translation of nanomedicine, Chem. Rev., 115, 11147, 10.1021/acs.chemrev.5b00116

Mitragotri, 2015, Accelerating the translation of nanomaterials in biomedicine, ACS Nano, 9, 6644, 10.1021/acsnano.5b03569

Maeda, 2000, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, J. Control. Release, 65, 271, 10.1016/S0168-3659(99)00248-5

Maeda, 2016, A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy – problems, solutions, and prospects, Microcirculation, 23, 173, 10.1111/micc.12228

Harrington, 2001, Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes, Clin. Cancer Res., 7, 243

Maeda, 2015, Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity, Adv. Drug Deliv. Rev., 91, 3, 10.1016/j.addr.2015.01.002

Wang, 2015, EPR or no EPR? The billion-dollar question, Sci. Transl. Med., 7, 10.1126/scitranslmed.aac8108

Morrison, 2018, Alnylam prepares to land first RNAi drug approval, Nat. Rev. Drug Discov., 17, 156, 10.1038/nrd.2018.20

Sun, 2017, Rational Design of cancer nanomedicine: nanoproperty integration and synchronization, Adv. Mater., 29, 1606628, 10.1002/adma.201606628

Du, 2018, Tumor-acidity-cleavable maleic acid amide (TACMAA): a powerful tool for designing smart nanoparticles to overcome delivery barriers in cancer nanomedicine, Acc. Chem. Res., 51, 2848, 10.1021/acs.accounts.8b00195

Chen, 2017, Sequentially responsive shell-stacked nanoparticles for deep penetration into solid tumors, Adv. Mater., 29, 10.1002/adma.201701170

Park, 2019, The beginning of the end of the nanomedicine hype, J. Control. Release, 305, 221, 10.1016/j.jconrel.2019.05.044

Das, 2019, Liposomal nanostructures for drug delivery in gastrointestinal cancers, J. Pharmacol. Exp. Ther., 370, 647, 10.1124/jpet.118.254797

Mellman, 2011, Cancer immunotherapy comes of age, Nature, 480, 480, 10.1038/nature10673

Sanmamed, 2018, A paradigm shift in cancer immunotherapy: from enhancement to normalization, Cell, 175, 313, 10.1016/j.cell.2018.09.035

van der Burg, 2016, Vaccines for established cancer: overcoming the challenges posed by immune evasion, Nat. Rev. Cancer, 16, 219, 10.1038/nrc.2016.16

Hollingsworth, 2019, Turning the corner on therapeutic cancer vaccines, NPJ Vaccines, 4, 7, 10.1038/s41541-019-0103-y

Irvine, 2015, Synthetic nanoparticles for vaccines and immunotherapy, Chem. Rev., 115, 11109, 10.1021/acs.chemrev.5b00109

Song, 2017, Nanomaterials for cancer immunotherapy, Biomaterials, 148, 16, 10.1016/j.biomaterials.2017.09.017

Kuai, 2017, Designer vaccine nanodiscs for personalized cancer immunotherapy, Nat. Mater., 16, 489, 10.1038/nmat4822

Furness, 2016, Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?, Immunotherapy, 8, 763, 10.2217/imt-2016-0064

Ott, 2017, An immunogenic personal neoantigen vaccine for patients with melanoma, Nature, 547, 217, 10.1038/nature22991

Sahin, 2017, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, Nature, 547, 222, 10.1038/nature23003

Gilboa, 2007, DC-based cancer vaccines, J. Clin. Invest., 117, 1195, 10.1172/JCI31205

Gardner, 2012, Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer, Hum. Vaccin. Immunother., 8, 534, 10.4161/hv.19795

Tanyi, 2018, Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer, Sci. Transl. Med., 10, 10.1126/scitranslmed.aao5931

Marabelle, 2017, Intratumoral immunotherapy: using the tumor as the remedy, Ann. Oncol., 28, 33, 10.1093/annonc/mdx683

Sagiv-Barfi, 2018, Eradication of spontaneous malignancy by local immunotherapy, Sci. Transl. Med., 10, 10.1126/scitranslmed.aan4488

Hammerich, 2019, Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination, Nat. Med., 25, 814, 10.1038/s41591-019-0410-x

Lynn, 2015, In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity, Nat. Biotechnol., 33, 1201, 10.1038/nbt.3371

Nuhn, 2018, Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses, Adv. Mater., 30, 10.1002/adma.201803397

Mottas, 2019, Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation, Biomaterials, 190-191, 111, 10.1016/j.biomaterials.2018.10.031

Kwong, 2011, Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy, Biomaterials, 32, 5134, 10.1016/j.biomaterials.2011.03.067

Song, 2018, Trapping of lipopolysaccharide to promote immunotherapy against colorectal cancer and attenuate liver metastasis, Adv. Mater., 30, 10.1002/adma.201805007

Das, 2019, Nanoparticle delivery of RIG-I agonist enables effective and safe adjuvant therapy in pancreatic cancer, Mol. Ther., 27, 507, 10.1016/j.ymthe.2018.11.012

Cheng, 2018, A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer, JCI Insight, 3, 120638, 10.1172/jci.insight.120638

Song, 2019, Leveraging biomaterials for cancer immunotherapy: targeting pattern recognition receptors, Mater. Today Nano, 5, 100029, 10.1016/j.mtnano.2019.100029

Thomas, 2014, Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response, Biomaterials, 35, 814, 10.1016/j.biomaterials.2013.10.003

Zhang, 2018, Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity, Nat. Commun., 9, 6, 10.1038/s41467-017-02251-3

Hewitt, 2019, Durable anticancer immunity from intratumoral administration of IL-23, IL-36 gamma, and OX40L mRNAs, Sci. Transl. Med., 11, 10.1126/scitranslmed.aat9143

Yang, 2019, Selectively potentiating hypoxia levels by combretastatin a4 nanomedicine: toward highly enhanced hypoxia-activated prodrug tirapazamine therapy for metastatic tumors, Adv. Mater., 31

Ueki, 2013, Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease, Nat. Commun., 4, 2735, 10.1038/ncomms3735

Trouet, 2001, Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer, Cancer Res., 61, 2843

Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596

Zou, 2016, PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations, Sci. Transl. Med., 8, 328rv4, 10.1126/scitranslmed.aad7118

Sharma, 2015, Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential, Cell, 161, 205, 10.1016/j.cell.2015.03.030

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239

Wang, 2019, Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy, Nat. Med., 25, 656, 10.1038/s41591-019-0374-x

Wang, 2019, Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3, Cell, 176, 334, 10.1016/j.cell.2018.11.010

Martins, 2019, Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance, Nat. Rev. Clin. Oncol., 16, 563, 10.1038/s41571-019-0218-0

Weber, 2012, Management of immune-related adverse events and kinetics of response with ipilimumab, J. Clin. Oncol., 30, 2691, 10.1200/JCO.2012.41.6750

Postow, 2018, Immune-related adverse events associated with immune checkpoint blockade, N. Engl. J. Med., 378, 158, 10.1056/NEJMra1703481

Remon, 2018, Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients, J. Thorac. Dis., 10, S1516, 10.21037/jtd.2017.12.52

Vonderheide, 2007, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody, J. Clin. Oncol., 25, 876, 10.1200/JCO.2006.08.3311

Wang, 2017, In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy, Nat. Biomed. Eng., 1, 10.1038/s41551-016-0011

Mi, 2018, A dual immunotherapy nanoparticle improves T-cell activation and cancer immunotherapy, Adv. Mater., 30

Robles-Carrillo, 2010, Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice, J. Immunol., 185, 1577, 10.4049/jimmunol.0903888

Shock, 2015, CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study, Arthritis Res. Ther., 17, 234, 10.1186/s13075-015-0757-4

Miao, 2017, Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors, Cancer Res., 77, 719, 10.1158/0008-5472.CAN-16-0866

Goodwin, 2016, Local and transient gene expression primes the liver to resist cancer metastasis, Sci. Transl. Med., 8, 364ra153, 10.1126/scitranslmed.aag2306

Miao, 2017, Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic cancer, ACS Nano, 11, 8690, 10.1021/acsnano.7b01786

Shen, 2018, Local blockade of interleukin 10 and C-X-C motif chemokine ligand 12 with nano-delivery promotes antitumor response in murine cancers, ACS Nano, 12, 9830, 10.1021/acsnano.8b00967

Liu, 2018, Nanoparticle-mediated trapping of wnt family member 5A in tumor microenvironments enhances immunotherapy for B-Raf proto-oncogene mutant melanoma, ACS Nano, 12, 1250, 10.1021/acsnano.7b07384

An, 2019, Locally trapping the C-C chemokine receptor type 7 by gene delivery nanoparticle inhibits lymphatic metastasis prior to tumor resection, Small, 15, 1805182, 10.1002/smll.201805182

Song, 2018, Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap, Nat. Commun., 9, 2237, 10.1038/s41467-018-04605-x

Twumasi-Boateng, 2018, Oncolytic viruses as engineering platforms for combination immunotherapy, Nat. Rev. Cancer, 18, 419, 10.1038/s41568-018-0009-4

Freedman, 2018, An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells, Cancer Res., 78, 6852, 10.1158/0008-5472.CAN-18-1750

Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967

June, 2018, CAR T cell immunotherapy for human cancer, Science, 359, 1361, 10.1126/science.aar6711

D’Aloia, 2018, CAR-T cells: the long and winding road to solid tumors, Cell Death Dis., 9, 282, 10.1038/s41419-018-0278-6

Kaiser, 2015, Towards a commercial process for the manufacture of genetically modified T cells for therapy, Cancer Gene Ther., 22, 72, 10.1038/cgt.2014.78

Fernanda Masri, 2019, Viral vector manufacturing: how to address current and future demands?, Cell Gene Ther. Insights, 5, 949, 10.18609/cgti.2019.104

Tang, 2018, Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery, Nat. Biotechnol., 36, 707, 10.1038/nbt.4181

Cole, 2005, Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells, Nat. Med., 11, 1073, 10.1038/nm1297

Stephan, 2010, Therapeutic cell engineering with surface-conjugated synthetic nanoparticles, Nat. Med., 16, 1035, 10.1038/nm.2198

Zheng, 2017, Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or noninternalizing receptors, ACS Nano, 11, 3089, 10.1021/acsnano.7b00078

Huang, 2015, Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells, Sci. Transl. Med., 7, 291ra94, 10.1126/scitranslmed.aaa5447

Zheng, 2013, In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes, J. Control. Release, 172, 426, 10.1016/j.jconrel.2013.05.037

Smith, 2017, In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers, Nat. Nanotechnol., 12, 813, 10.1038/nnano.2017.57

Krishnamurthy, 2018, Bispecific antibodies for cancer therapy: a review, Pharmacol. Ther., 185, 122, 10.1016/j.pharmthera.2017.12.002

Chames, 2009, Bispecific antibodies for cancer therapy: the light at the end of the tunnel?, mAbs, 1, 539, 10.4161/mabs.1.6.10015

Duell, 2019, Bispecific antibodies in the treatment of hematologic malignancies, Clin. Pharmacol. Ther., 106, 781, 10.1002/cpt.1396

Baeuerle, 2009, Bispecific T-cell engaging antibodies for cancer therapy, Cancer Res., 69, 4941, 10.1158/0008-5472.CAN-09-0547

Dreier, 2003, T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct, J. Immunol., 170, 4397, 10.4049/jimmunol.170.8.4397

Yu, 2017, Recent advances of bispecific antibodies in solid tumors, J. Hematol. Oncol., 10, 155, 10.1186/s13045-017-0522-z

Brischwein, 2007, Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class, J. Immunother., 30, 798, 10.1097/CJI.0b013e318156750c

Yuan, 2017, Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy, Nat. Nanotechnol., 12, 763, 10.1038/nnano.2017.69

Nunez-Prado, 2015, The coming of age of engineered multivalent antibodies, Drug Discov. Today, 20, 588, 10.1016/j.drudis.2015.02.013

Chiu, 2007, Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs, Mol. Cancer Ther., 6, 844, 10.1158/1535-7163.MCT-06-0159

Cheng, 2018, Reprogramming exosomes as nanoscale controllers of cellular immunity, J. Am. Chem. Soc., 140, 16413, 10.1021/jacs.8b10047

Popov, 2011, Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity, Nanomedicine, 6, 1575, 10.2217/nnm.11.50